How to compare the efficiency of albumin-bound and nonalbumin-bound contrast agents in vivo: The concept of dynamic relaxivity

Investigative Radiology

Volumn 40, Issue 9, 2005, Pages 565-573

  Port, Marc ^a   Corot, Claire ^a   Violas, Xavier ^a   Robert, Philippe ^a   Raynal, Isabelle ^a   Gagneur, Georgia ^a  

^a Laboratoire Guerbet   (France)

Author keywords

Albumin binding relaxivity; Blood pool agent; Dynamic relaxivity; Gd BOPTA; MS325; P792

Indexed keywords

ALBUMIN; CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADOBENIC ACID; GADOFOSVESET; GADOMELITOL; GADOTERIC ACID; MEGLUMINE DIATRIZOATE PLUS SODIUM DIATRIZOATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; IN VIVO STUDY; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RABBIT;

EID: 23944455381     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rli.0000175388.98721.9b     Document Type: Article

References (21)

1. Corot C, Violas X, Robert P, et al. Comparison of different types of blood pool agents (P792, MS325, USPIO) in a rabbit MR angiography-like protocol. Invest Radiol. 2003;6:311-319.
2. Corot C, Violas X, Robert P, et al. Pharmacokinetics of three gadolinium chelates with different molecular sizes shortly after intravenous injection in rabbits: relevance to MR angiography. Invest Radiol. 2000;35:213-218.
3. Corot C, Violas X, Robert P, et al. Arterial concentration profiles of two blood pool agents and Gd-DOTA after intravenous injection in rabbits. Acad Radiol. 2002;9(suppl 1):S137-S139.
4. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins. Invest Radiol. 1997;32:780-796.
5. Wyttenbach R, Gianella S, Arceli M, et al. Prospective blinded evaluation of Gd-DOTA versus Gd-BOPTA enhanced peripheral MR angiography as compared with digital subtraction angiography. Radiology. 2003;227:261-269.
6. Bourasset F, Dencausse A, Bourrinet P, et al. Comparison of plasma and peritoneal concentrations of various categories of MRI blood pool agents in a murine experimental pharmacokinetic model. MAGMA. 2001;12: 81-87.
7. Marchand B, Douek P, Benderbous S, et al. Pilot MR evaluation of pharmacokinetics and relaxivity of specific blood pool agents for MR angiography. Invest Radiol. 2000;35:41-49.
8. Taupitz M, Schnorr J, Wagner S, et al. Coronary magnetic resonance angiography: experimental evaluation of the new rapid clearance blood pool contrast medium P792. Magn Reson Med. 2001;46:932-938.
9. Lin W, Abdendschein D, Celik A, et al. Intravascular contrast agent improves magnetic resonance angiography of carotid arteries in mini-pigs. J Magn Reson Imaging. 1997;7:963-971.
10. Debiao L, Dolan R, Walovitch R, et al. Three dimensional MRI of coronary arteries using an intravascular contrast agent. Magn Reson Med. 1998;39:1014-1018.
11. Gaillard S, Kubiak C, Stolz C, et al. Safety and pharmacokinetics of P792, a new blood-pool agent: results of clinical testing in non-patient volunteers. Invest Radiol. 2002;37:161-166.
12. Port M, Corot C, Raynal I, et al. Physicochemical and biological evaluation of P792, a rapid clearance blood pool agent for magnetic resonance imaging. Invest Radiol. 2001;36:445-454.
13. Port M, Corot C, Rousseaux O, et al. P792: a rapid clearance blood pool agent for magnetic resonance imaging: preliminary results. MAGMA. 2001;12:121-127.
14. Lauffer R, Parmelee D, Dunham S, et al. MS-325: albumin-targeted contrast agent for MR angiography. Radiology. 1998;207:529-538.
15. Parmelee D, Walovitsch C, Quellet H, et al. Preclinical evaluation of the pharmacokinetics, biodistribution and elimination of MS-325, a blood pool agent for magnetic resonance imaging. Invest Radiol. 1997;32:741-747.
16. Bluemke D, Stillman A, Bis K, et al. Carotid MR angiography: phase II study of safety and efficacy for MS-325. Radiology. 2001;219:114-122.
17. Grist T, Korosec F, Peters D, et al. Steady-state and dynamic MR angiography with MS-325: initial experience in humans. Radiology. 1998;207:539-544.
18. Muller R, Raduchel B, Laurent S, et al. Physicochemical characterization of MS-325, a new gadolinium complex by multinuclear relaxometry. Eur J Inorg Chem. 1999;1949-1955.
19. Caravan P, Cloutier NJ, Greenfield MT, et al. The interaction of MS325 with human serum albumin and its effect on proton relaxation rates. J Am Chem Soc. 2002;124:3152-3162.
20. Caravan P, Ellison JJ, McMurry TJ, et al. Gadolinium chelates as MRI contrast agents: structure, dynamics and applications. Chem Rev. 1999; 99:2293-2352.
21. Dewey M, Kaufels N, Laule M, et al. Magnetic resonance imaging of myocardial perfusion and viability using a blood pool contrast agent. Invest Radiol. 2004;39:498-505.